Abcam, ab290744, Anti-MAVS antibody [EPR26357-91] (BSA and Azide free)

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MAVS antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF, Flow Cyt (Intra), IP and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR26357-288,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, WB, Flow Cyt (Intra), ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MAVS also known as mitochondrial antiviral-signaling protein is a critical adaptor protein involved in the innate immune response to viral infections. This protein with a molecular weight of approximately 56 kDa is expressed on the mitochondrial membrane. It plays a major role in antiviral defense by transmitting signals from cytosolic pattern recognition receptors like RIG-I-like receptors to initiate downstream immune responses. MAVS can also be referred to as IPS-1 VISA or CARDIF in scientific literature.
Biological function summary
The MAVS protein activates important signaling cascades to produce type I interferons and other cytokines which are essential in the antiviral response. MAVS forms a complex with other proteins on the mitochondrial membrane helping to coordinate a rapid immune reaction to viral pathogens. It acts by amplifying the signal from RIG-I and MDA5 facilitating their role in the recognition of viral RNA. By recruiting downstream signaling molecules MAVS enables the activation of transcription factors like IRF3 and NF-kB.
Pathways
MAVS plays a central role in the signaling pathways that regulate innate immunity including the RIG-I-like receptor signaling pathway and the NF-kB pathway. It interacts with various proteins such as TRIF and STING in the pathways to modulate immune responses. These pathways help trigger the production of antiviral substances and maintain homeostasis within the body's defense mechanisms. MAVS provides a platform for the assembly of signaling complexes which are necessary for the propagation and amplification of the immune response signal.
MAVS is associated with conditions such as viral infections and autoimmune diseases. Dysregulation of MAVS activity has been linked to systemic lupus erythematosus where abnormal immune signaling may occur. MAVS also has connections with other proteins such as TRAF3 and TRAF6 which contribute to disease pathogenesis. Understanding the role of MAVS in these conditions may provide insights into therapeutic targets for improving disease outcomes.